Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Hedeker Wealth LLC

Hedeker Wealth LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 28.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,615 shares of the medical research company's stock after selling 3,025 shares during the quarter. Hedeker Wealth LLC's holdings in Thermo Fisher Scientific were worth $4,042,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Phoenix Holdings Ltd. increased its holdings in Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company's stock valued at $4,750,000 after buying an additional 1,654 shares during the last quarter. DMC Group LLC boosted its stake in Thermo Fisher Scientific by 16.5% in the third quarter. DMC Group LLC now owns 592 shares of the medical research company's stock valued at $300,000 after acquiring an additional 84 shares during the period. Montchanin Asset Management LLC boosted its stake in Thermo Fisher Scientific by 1.1% in the second quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company's stock valued at $2,374,000 after acquiring an additional 50 shares during the period. Check Capital Management Inc. CA acquired a new position in shares of Thermo Fisher Scientific during the third quarter worth approximately $219,000. Finally, Tsfg LLC boosted its position in shares of Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company's stock worth $132,000 after buying an additional 19 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 1.6 %

NYSE:TMO traded up $8.85 during trading hours on Friday, hitting $579.46. 1,181,250 shares of the stock traded hands, compared to its average volume of 1,583,425. The firm has a 50 day moving average price of $569.39 and a 200 day moving average price of $523.29. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The firm has a market cap of $220.95 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 2.42 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the business posted $5.40 earnings per share. Thermo Fisher Scientific's revenue for the quarter was down 4.9% compared to the same quarter last year. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio is 10.10%.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company's stock, valued at $7,250,362. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TMO. Barclays downgraded Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and boosted their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They issued an "outperform" rating and a $575.00 target price for the company. Royal Bank of Canada upped their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Evercore ISI upped their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, Raymond James upped their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $599.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.